10th Edition of The International Pharmacopoeia
Recommendation
4-6 March 2025
Management, Supply and Quality Assurance of Clinical Trials
The International Pharmacopoeia (Ph. Int.) contains recommended procedures for analysis and specifications for pharmaceutical substances (active pharmaceutical ingredients, APIs) and dosage forms. According to the WHO (World Health Organization) it is intended to serve as source for reference or adaptation by any WHO Member State. The Ph. Int. has legal status, whenever a national or regional authority refers to it in appropriate legislation.
Compared to other pharmacopoeias (e.g. Ph. Eur., USP, JP), "priority is given to medicines included in the WHO Model List of Essential Medicines and to medicines which are important for WHO health programmes and for which other pharmacopoeias do not offer any test specifications". Moreover, the needs of developing countries are taken into account.
The International Pharmacopoeia, Tenth Edition, 2020 - Content Overview
- General Notices (includes information on storage, stability, labelling, identity, tests & assays, accuracy and precision, calculation of results, impurities, reference substances, etc.)
- Appendices to the General Notices
Abbreviations and symbols
Units of measurement
Names, symbols, and relative atomic masses of certain elements - Monographs
Pharmaceutical substances
Dosage forms
Radiopharmaceuticals - Methods of Analysis
1. Physical and Physicochemical Methods
2. Chemical methods
3. Biological methods
4. Methods for materials of plant origin
5. Pharmaceutical technical procedures - Infrared reference spectra
- Reagents, test solutions and volumetric solutions
- Supplementary information
The International Pharmacopoeia is available online free for use.
Related GMP News
20.11.2024The EU Qualified Person - What's it all about?
13.11.2024Glossary of ICH Terms and Definitions published
02.10.2024MHRA: New Rules for Manufacturers and Wholesalers after Brexit
24.09.2024What is RCA (Root Cause Analysis)?
18.09.2024Lack of GMP Training and related Documentation: What Deviations can be found in FDA Warning Letters?
04.09.2024Switzerland: Changes for the Qualification of QPs (Responsible Person; RP in Switzerland)